Engineering strategies for allogeneic solid tissue acceptance
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10773/34363 |
Resumo: | Systemic immunosuppressants have allowed the transplantation of life-saving organs. However, they cause deleterious effects and long-term graft failure. Strategies promoting allogeneic graft acceptance and the maintenance of immunological competence have been proposed. Cell-based tolerance-inducing strategies that preserve immune competence have already extended human allograft acceptance, although toxic side effects or difficult reproduction of observed effects in humans have counteracted their clinical translation. Localized tolerance/immunosuppression mediated through bioengineered setups comprising immunomodulatory biomaterials and/or tissue engineering-inspired tools already achieved allograft acceptance in murine models and are game changing in the field. Such advances have contributed to unveiling the complex interplay of immune cells and allogeneic transplants. Advances in allogeneic transplantation of solid organs and tissues depend on our understanding of mechanisms that mediate the prevention of graft rejection. For the past decades, clinical practice has established guidelines to prevent allograft rejection, which mostly rely on the intake of nontargeted immunosuppressants as the gold standard. However, such lifelong regimens have been reported to trigger severe morbidities and commonly fail in preventing late allograft loss. In this review, the biology of allogeneic rejection and self-tolerance is analyzed, as well as the mechanisms of cellular-based therapeutics driving suppression and/or tolerance. Bioinspired engineering strategies that take advantage of cells, biomaterials, or combinations thereof to prevent allograft rejection are addressed, as well as biological mechanisms that drive their efficacy. |
id |
RCAP_44d3048fa3e1da3f58889335f4e30088 |
---|---|
oai_identifier_str |
oai:ria.ua.pt:10773/34363 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Engineering strategies for allogeneic solid tissue acceptanceAllogeneic transplantationBioengineering acceptance-inducing strategiesCellular/acellular therapeuticsTissue engineeringSystemic immunosuppressants have allowed the transplantation of life-saving organs. However, they cause deleterious effects and long-term graft failure. Strategies promoting allogeneic graft acceptance and the maintenance of immunological competence have been proposed. Cell-based tolerance-inducing strategies that preserve immune competence have already extended human allograft acceptance, although toxic side effects or difficult reproduction of observed effects in humans have counteracted their clinical translation. Localized tolerance/immunosuppression mediated through bioengineered setups comprising immunomodulatory biomaterials and/or tissue engineering-inspired tools already achieved allograft acceptance in murine models and are game changing in the field. Such advances have contributed to unveiling the complex interplay of immune cells and allogeneic transplants. Advances in allogeneic transplantation of solid organs and tissues depend on our understanding of mechanisms that mediate the prevention of graft rejection. For the past decades, clinical practice has established guidelines to prevent allograft rejection, which mostly rely on the intake of nontargeted immunosuppressants as the gold standard. However, such lifelong regimens have been reported to trigger severe morbidities and commonly fail in preventing late allograft loss. In this review, the biology of allogeneic rejection and self-tolerance is analyzed, as well as the mechanisms of cellular-based therapeutics driving suppression and/or tolerance. Bioinspired engineering strategies that take advantage of cells, biomaterials, or combinations thereof to prevent allograft rejection are addressed, as well as biological mechanisms that drive their efficacy.Cell Press2022-08-01T17:51:09Z2021-06-01T00:00:00Z2021-06-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10773/34363eng1471-491410.1016/j.molmed.2021.03.005Sousa, Ana RitaMano, João F.Oliveira, Mariana B.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:06:24Zoai:ria.ua.pt:10773/34363Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:05:44.078267Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Engineering strategies for allogeneic solid tissue acceptance |
title |
Engineering strategies for allogeneic solid tissue acceptance |
spellingShingle |
Engineering strategies for allogeneic solid tissue acceptance Sousa, Ana Rita Allogeneic transplantation Bioengineering acceptance-inducing strategies Cellular/acellular therapeutics Tissue engineering |
title_short |
Engineering strategies for allogeneic solid tissue acceptance |
title_full |
Engineering strategies for allogeneic solid tissue acceptance |
title_fullStr |
Engineering strategies for allogeneic solid tissue acceptance |
title_full_unstemmed |
Engineering strategies for allogeneic solid tissue acceptance |
title_sort |
Engineering strategies for allogeneic solid tissue acceptance |
author |
Sousa, Ana Rita |
author_facet |
Sousa, Ana Rita Mano, João F. Oliveira, Mariana B. |
author_role |
author |
author2 |
Mano, João F. Oliveira, Mariana B. |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Sousa, Ana Rita Mano, João F. Oliveira, Mariana B. |
dc.subject.por.fl_str_mv |
Allogeneic transplantation Bioengineering acceptance-inducing strategies Cellular/acellular therapeutics Tissue engineering |
topic |
Allogeneic transplantation Bioengineering acceptance-inducing strategies Cellular/acellular therapeutics Tissue engineering |
description |
Systemic immunosuppressants have allowed the transplantation of life-saving organs. However, they cause deleterious effects and long-term graft failure. Strategies promoting allogeneic graft acceptance and the maintenance of immunological competence have been proposed. Cell-based tolerance-inducing strategies that preserve immune competence have already extended human allograft acceptance, although toxic side effects or difficult reproduction of observed effects in humans have counteracted their clinical translation. Localized tolerance/immunosuppression mediated through bioengineered setups comprising immunomodulatory biomaterials and/or tissue engineering-inspired tools already achieved allograft acceptance in murine models and are game changing in the field. Such advances have contributed to unveiling the complex interplay of immune cells and allogeneic transplants. Advances in allogeneic transplantation of solid organs and tissues depend on our understanding of mechanisms that mediate the prevention of graft rejection. For the past decades, clinical practice has established guidelines to prevent allograft rejection, which mostly rely on the intake of nontargeted immunosuppressants as the gold standard. However, such lifelong regimens have been reported to trigger severe morbidities and commonly fail in preventing late allograft loss. In this review, the biology of allogeneic rejection and self-tolerance is analyzed, as well as the mechanisms of cellular-based therapeutics driving suppression and/or tolerance. Bioinspired engineering strategies that take advantage of cells, biomaterials, or combinations thereof to prevent allograft rejection are addressed, as well as biological mechanisms that drive their efficacy. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-01T00:00:00Z 2021-06-01 2022-08-01T17:51:09Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10773/34363 |
url |
http://hdl.handle.net/10773/34363 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1471-4914 10.1016/j.molmed.2021.03.005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Cell Press |
publisher.none.fl_str_mv |
Cell Press |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137712527114240 |